Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Aug 26;13(1):120.
doi: 10.1186/s12920-020-00760-7.

Genome-wide association meta-analysis for early age-related macular degeneration highlights novel loci and insights for advanced disease

Affiliations
Meta-Analysis

Genome-wide association meta-analysis for early age-related macular degeneration highlights novel loci and insights for advanced disease

Thomas W Winkler et al. BMC Med Genomics. .

Abstract

Background: Advanced age-related macular degeneration (AMD) is a leading cause of blindness. While around half of the genetic contribution to advanced AMD has been uncovered, little is known about the genetic architecture of early AMD.

Methods: To identify genetic factors for early AMD, we conducted a genome-wide association study (GWAS) meta-analysis (14,034 cases, 91,214 controls, 11 sources of data including the International AMD Genomics Consortium, IAMDGC, and UK Biobank, UKBB). We ascertained early AMD via color fundus photographs by manual grading for 10 sources and via an automated machine learning approach for > 170,000 photographs from UKBB. We searched for early AMD loci via GWAS and via a candidate approach based on 14 previously suggested early AMD variants.

Results: Altogether, we identified 10 independent loci with statistical significance for early AMD: (i) 8 from our GWAS with genome-wide significance (P < 5 × 10- 8), (ii) one previously suggested locus with experiment-wise significance (P < 0.05/14) in our non-overlapping data and with genome-wide significance when combining the reported and our non-overlapping data (together 17,539 cases, 105,395 controls), and (iii) one further previously suggested locus with experiment-wise significance in our non-overlapping data. Of these 10 identified loci, 8 were novel and 2 known for early AMD. Most of the 10 loci overlapped with known advanced AMD loci (near ARMS2/HTRA1, CFH, C2, C3, CETP, TNFRSF10A, VEGFA, APOE), except two that have not yet been identified with statistical significance for any AMD. Among the 17 genes within these two loci, in-silico functional annotation suggested CD46 and TYR as the most likely responsible genes. Presence or absence of an early AMD effect distinguished the known pathways of advanced AMD genetics (complement/lipid pathways versus extracellular matrix metabolism).

Conclusions: Our GWAS on early AMD identified novel loci, highlighted shared and distinct genetics between early and advanced AMD and provides insights into AMD etiology. Our data provide a resource comparable in size to the existing IAMDGC data on advanced AMD genetics enabling a joint view. The biological relevance of this joint view is underscored by the ability of early AMD effects to differentiate the major pathways for advanced AMD.

Keywords: Age-related macular degeneration (AMD); Automated phenotyping; CD46; Early AMD; Genome-wide association study (GWAS); International AMD genomics consortium (IAMDGC); Machine-learning; Meta-analysis; TYR; UK biobank (UKBB).

PubMed Disclaimer

Conflict of interest statement

M.S. receives funding from Pfizer Inc. for a project not related to this research. Retinal grading of the NICOLA study was supported by Novartis (for R.E.H) and Bayer (for Usha Chakravarthy, not a co-author). A.K.S. received financial and research support by Heidelberg Engineering, Novartis, Bayer Vital and Allergen without a link to the content of this work. I.M.H. received funding from Roche Diagnostics for a project not related to this research. None of the other authors have any conflicts of interest.

Figures

Fig. 1
Fig. 1
Early AMD meta-analysis. Shown are the association results of the meta-analysis for early AMD: a by their position on the genome (Manhattan plot) with color indicating whether the locus was previously identified by Holliday et al. [12] (blue), novel for early AMD (red), or among the other advanced AMD loci identified by Fritsche et al. [9] (green); and b their distribution (QQ plot)
Fig. 2
Fig. 2
Advanced vs early AMD effect sizes. Shown are advanced AMD effect sizes contrasted to early AMD effect sizes (effect sizes as log odds ratios) for the 34 known advanced AMD variants [9] (blue or green for Pearly < 0.05 or Pearly ≥ 0.05, respectively) and for the two novel (early) AMD variants (red, near CD46, TYR). Detailed results are shown in Table S16
Fig. 3
Fig. 3
Etiological models and the respective expected association of a variant with early and advanced AMD

References

    1. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet Elsevier. 2012;379:1728–1738. - PubMed
    1. Garrity ST, Sarraf D, Freund KB, Sadda SR. Multimodal imaging of Nonneovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2018;59:AMD48–AMD64. - PubMed
    1. Forte R, Querques G, Querques L, Massamba N, Le Tien V, Souied EH. Multimodal imaging of dry age-related macular degeneration. Acta Ophthalmol. 2012;90:281–287. - PubMed
    1. Klein R, Meuer SM, Myers CE, Buitendijk GHS, Rochtchina E, Choudhury F, et al. Harmonizing the classification of age-related macular degeneration in the three-continent AMD consortium. Ophthalmic Epidemiol. 2014;21:14–23. - PMC - PubMed
    1. Brandl C, Zimmermann ME, Günther F, Barth T, Olden M, Schelter SC, et al. On the impact of different approaches to classify age-related macular degeneration: results from the German AugUR study. Sci Rep. 2018;8:1–10. - PMC - PubMed

Publication types

Substances

Grants and funding